Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine targeting KTN1 to treat skin squamous cell carcinoma

A squamous cell carcinoma, KTN1 technology, used in skin diseases, drug combinations, anti-tumor drugs, etc., can solve the problems of unclear molecular biological mechanisms and no research reports

Inactive Publication Date: 2017-05-17
SOUTHERN MEDICAL UNIVERSITY
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, many studies on KTN1 in tumors are still in the preliminary stage
For example, there is currently no research report on how KTN1 functions in squamous cell carcinoma of the skin
At the same time, its underlying molecular biological mechanism is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine targeting KTN1 to treat skin squamous cell carcinoma
  • Medicine targeting KTN1 to treat skin squamous cell carcinoma
  • Medicine targeting KTN1 to treat skin squamous cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] Application of a reagent targeting silencing KTN1 or downregulating the expression of KTN1 in the preparation of a drug for treating skin squamous cell carcinoma.

[0023] Further, the reagents targeting silencing KTN1 or downregulating the expression of KTN1 are targeting KTN1 siRNA.

[0024] In particular, the sequence of siRNA is:

[0025] siKTN1_1: GAGAUUGUGUUGAAAGAAA (SEQ ID NO: 1);

[0026] and at least one of siKTN1_2: CAGGAAAGCUACAGCAAGA (SEQ ID NO: 2).

[0027] More preferably, at least part of the nucleic acid in the siRNA is modified to improve its binding capacity. At least part of the nucleic acid in the siRNA is modified with LNA.

[0028] The technical solution of the present invention will be further described below in combination with experiments.

[0029] Materials and Methods:

[0030] ①The human skin squamous cell carcinoma cell line A431 cells were selected and incubated at 37°C and 5% CO 2 Under culture conditions, use 10% FBSDMEM medium for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicine targeting KTN1 to treat skin squamous cell carcinoma. An inventor uses an EGFR (epidermal growth factor receptor) highly-expressed cell strain A431 with the skin squamous cell carcinoma characteristic as an experiment object; after proofing by an experiment, the targeting reduction of KTN1 can inhibit the expression of the EGFR which influences the proliferation, transfer and invasion ability of tumor cells, so as to finally improve or treat the skin squamous cell carcinoma.

Description

technical field [0001] The invention relates to a new technology for improving or treating skin squamous cell carcinoma. Background technique [0002] Cutaneous squamous cell carcinoma (SCC) is a malignant tumor arising from keratinocytes in epithelial tissue. According to statistics, the incidence of SCC is second only to basal cell carcinoma among all skin malignancies. The etiology of SCC is complex, and factors such as UV radiation, HPV infection, organ transplantation, and chemical agents are closely related to the pathogenesis of SCC. [0003] The clinical manifestations of SCC vary widely and are related to the location and type of disease. SCC usually occurs in exposed parts of the skin, but it can also occur in any other part of the body. About 55% occur in the head and neck, about 18% occur in the back of the hand and the extensor side of the forearm, 13% occur in the lower extremities, and 4% occur in the shoulder and back. 3% occurred in the upper limbs, and 7...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/713A61P35/00A61P17/00
CPCA61K45/00A61K31/713
Inventor 丁振华周良高琳李姗姗
Owner SOUTHERN MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com